This WLF Litigation Division feature highlights WLF court and agency filings, as well as decisions issued in response to WLF’s filings. In this edition, we list March 2025 filings and decisions.
Click on the PDF button above for the full report.
New Filings
- WLF asks the Supreme Court to rein in “no-injury” class actions. (State Farm v. Jama)
- WLF urges the en banc Ninth Circuit to return to the ordinary test for determining whether a statute applies retroactively to pre-enactment conduct. (Ratha v. Rubicon Resources LLC)
- WLF asks the Ninth Circuit to reverse a trial court decision that failed to require common proof of harm for class certification. (Drake v. Bayer Healthcare LLC)
- WLF asks the FDA to withdraw a proposed rule that would nearly eliminate nicotine from conventional cigarettes and cigars. (In re Withdrawal of FDA Tobacco Product Standard for Nicotine Yield Proposed Rule)
- WLF urges the Delaware Supreme Court to reverse an unprecedented decision that nullified Tesla shareholders’ ratification of their CEO’s compensation. (In re Tesla Inc. Derivative Action)
- WLF urges Eleventh Circuit to declare False Claims Act’s qui tam provision unconstitutional. (U.S. ex rel. Zafirov v. Florida Medical Associates)
- WLF asks the Supreme Court to take up a controversial personal-jurisdiction case. (IQVIA v. Superior Court)
- WLF asks the Supreme Court to vindicate Article III’s strict standing limits in class actions. (Labcorp v. Davis)
Results
- The Supreme Court Texas denies mandamus relief in a controversial qui tam case. (In re Gilead Sciences Inc.)